Synthetic long peptide-based vaccine formulations for induction of cell mediated immunity: A comparative study of cationic liposomes and PLGA nanoparticles

Journal of Controlled Release

Volumn 226, Issue , 2016, Pages 98-106

  Varypataki, Eleni Maria ^a   Silva, Ana Luisa ^a   Barnier Quer, Christophe ^b   Collin, Nicolas ^b   Ossendorp, Ferry ^c   Jiskoot, Wim ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cationic liposomes; Cellular immune response; PLGA nanoparticles; Synthetic long peptides; TLR ligands

Indexed keywords

ANTIGENS; CELLS; DISEASES; IMMUNE SYSTEM; LIGANDS; LIPOSOMES; MAMMALS; NANOPARTICLES; PEPTIDES; T-CELLS; VACCINES;

CATIONIC LIPOSOMES; CELL-MEDIATED IMMUNE; COMPARATIVE STUDIES; DELIVERY SYSTEMS; DENDRITIC CELLS (DCS); IMMUNE RESPONSE; NANO PARTICULATES; PLGA NANOPARTICLES;

CYTOLOGY;

LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONTANIDE ISA 51; NANOPARTICLE; OVA24 OVA17 VACCINE; OVA24 VACCINE; PEPTIDE VACCINE; POLYGLACTIN; SQUALENE; TUMOR VACCINE; UNCLASSIFIED DRUG; CANCER VACCINE; CATION; LACTIC ACID; OVALBUMIN; PEPTIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXICITY; CYTOTOXICITY ASSAY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; IMMUNIZATION; IMMUNOLOGY; NEOPLASMS;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CATIONS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION; LACTIC ACID; LIPOSOMES; MICE, INBRED C57BL; NANOPARTICLES; NEOPLASMS; OVALBUMIN; PEPTIDES; POLYGLYCOLIC ACID; VACCINES, SYNTHETIC;

EID: 84958212254     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.02.018     Document Type: Article

References (46)

1. M. Black, and et al. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists Expert Rev. Vaccines 9 2 2010 157 173
2. R.A. Rosalia, and et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation Eur. J. Immunol. 43 10 2013 2554 2565
3. M.S. Bijker, and et al. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation Eur. J. Immunol. 38 4 2008 1033 1042
4. S. Zwaveling, and et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J. Immunol. 169 1 2002 350 358
5. F. Ossendorp, and et al. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors J. Exp. Med. 187 5 1998 693 702
6. + CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity J. Immunol. 179 8 2007 5033 5040
7. A. Salvador, and et al. An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines J. Drug Deliv. 2011 2011 181646
8. L.J. Peek, C.R. Middaugh, and C. Berkland Nanotechnology in vaccine delivery Adv. Drug Deliv. Rev. 60 8 2008 915 928
9. G.G. Kenter, and et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N. Engl. J. Med. 361 19 2009 1838 1847
10. C.J. Melief Synthetic vaccine for the treatment of lesions caused by high risk human papilloma virus Cancer J. 17 5 2011 300 301
11. C.J. Melief Treatment of established lesions caused by high-risk human papilloma virus using a synthetic vaccine J. Immunother. 35 3 2012 215 216
12. C.L. Chiang, L.E. Kandalaft, and G. Coukos Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines Int. Rev. Immunol. 30 2-3 2011 150 182
13. W.J. van Driel, and et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial Eur. J. Cancer 35 6 1999 946 952
14. C.L. Slingluff Jr., and et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: Immunologic and clinical outcomes Clin. Cancer Res. 7 10 2001 3012 3024
15. G.G. Kenter, and et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity Clin. Cancer Res. 14 1 2008 169 177
16. J. Aucouturier, S. Ascarateil, and L. Dupuis The use of oil adjuvants in therapeutic vaccines Vaccine 24 Suppl. 2 2006 S44 S45
17. P.P. Leenaars, and et al. Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice Lab. Anim. 32 4 1998 387 406
18. P. Elamanchili, and et al. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells J. Immunother. 30 4 2007 378 395
19. M.D. Joshi, and et al. Targeting tumor antigens to dendritic cells using particulate carriers J. Control. Release 161 1 2012 25 37
20. S.T. Reddy, M.A. Swartz, and J.A. Hubbell Targeting dendritic cells with biomaterials: Developing the next generation of vaccines Trends Immunol. 27 12 2006 573 579
21. A.L. Silva, and et al. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: Low-burst release is crucial for efficient CD8(+) T cell activation Eur. J. Pharm. Biopharm. 83 3 2013 338 345
22. E.M. Varypataki, and et al. Cationic liposomes loaded with a synthetic long Peptide and poly(i:C): A defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity AAPS J. 17 1 2015 216 226
23. J. Westdijk, and et al. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains Vaccine 31 9 2013 1298 1304
24. R. Ventura, and et al. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia Vaccine 31 12 2013 1641 1645
25. G.G. Zom, and et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates Cancer Immunol. Res. 2 8 2014 756 764
26. F. Ossendorp, and et al. Importance of CD4(+) T helper cell responses in tumor immunity Immunol. Lett. 74 1 2000 75 79
27. + T cells: When, where, and how Annu. Rev. Immunol. 24 2006 519 540
28. K. Palucka, and J. Banchereau Dendritic-cell-based therapeutic cancer vaccines Immunity 39 1 2013 38 48
29. + T-cell help Blood 109 12 2007 5318 5326
30. E. Schlosser, and et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses Vaccine 26 13 2008 1626 1637
31. R.A. Rosalia, and et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Biomaterials 40 2015 88 97
32. + T cell responses predict therapeutic efficacy against tumors J. Immunol. 189 7 2012 3397 3403
33. M.A. Swartz The physiology of the lymphatic system Adv. Drug Deliv. Rev. 50 1-2 2001 3 20
34. J.P. Girard, C. Moussion, and R. Forster HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes Nat. Rev. Immunol. 12 11 2012 762 773
35. M.O. Oyewumi, A. Kumar, and Z. Cui Nano-microparticles as immune adjuvants: Correlating particle sizes and the resultant immune responses Expert Rev. Vaccines 9 9 2010 1095 1107
36. V.B. Joshi, S.M. Geary, and A.K. Salem Biodegradable particles as vaccine delivery systems: Size matters AAPS J. 15 1 2013 85 94
37. J.P. Amorij, and et al. Towards tailored vaccine delivery: Needs, challenges and perspectives J. Control. Release 161 2 2012 363 376
38. A.L. Silva, and et al. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation Vaccine 33 7 2015 847 854
39. Y. Ataman-Onal, and et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models J. Control. Release 112 2 2006 175 185
40. R.E. Serda Particle platforms for cancer immunotherapy Int. J. Nanomedicine 8 2013 1683 1696
41. C. Foged, and et al. Interaction of dendritic cells with antigen-containing liposomes: Effect of bilayer composition Vaccine 22 15-16 2004 1903 1913
42. G. Chikh, and M.P. Schutze-Redelmeier Liposomal delivery of CTL epitopes to dendritic cells Biosci. Rep. 22 2 2002 339 353
43. T. Nakanishi, and et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins J. Control. Release 61 1-2 1999 233 240
44. W. Chen, W. Yan, and L. Huang A simple but effective cancer vaccine consisting of an antigen and a cationic lipid Cancer Immunol. Immunother. 57 4 2008 517 530
45. D.P. Vangasseri, and et al. Immunostimulation of dendritic cells by cationic liposomes Mol. Membr. Biol. 23 5 2006 385 395
46. C.M. Fehres, and et al. Understanding the biology of antigen cross-presentation for the design of vaccines against cancer Front. Immunol. 5 2014 149